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Abstract
Background: (TA) n repeat sequence (rs8175347) of UGT1A1 gene promoter polymorphism is associated with
serum bilirubin levels and gallstones among different sickle cell anaemia (SCA) populations. There are no data on
UGT1A1 polymorphisms and their impact on Nigerian SCA patients. In this study, we determined the distribution of
the UGT1A1 (TA) n genotypes among a group of young Nigerian SCA patients and healthy controls. In addition, the
influence of UGT1A1 (TA) n genotypes on the laboratory and clinical events among the patients was determined.
Methods: The distribution of the UGT1A1 (TA) n genotypes among 101 young Nigerian SCA patients and 64
normal appropriate controls were determined and studied. The UGT1A1 (TA) n genotypes were further classified
into subgroups and used to differentiate the clinical events and laboratory parameters of the patients.
Results: Four (TA) n alleles:(TA)5, 6, 7, and 8 were found. These were associated with 10 genotypes: TA5/5, 5/6, 5/7, 5/8,
6/6, 6/7, 6/8, 7/7, 7/8, 8/8. The normal (wild-type)-(TA) 6/6), low- (TA) 7/7, 7/8, 8/8), intermediate- (TA) 5/7, 5/8, 6/7, 6/8),
and high-activity (TA) 5/5, 5/6,) genotypes were found in 24.8, 24.8, 41.5, and 8.9% patients and 20.3, 15.6, 61, and 3.1%
controls respectively. The general genotype distribution of the patients and control group were not significantly
different. There were significant differences in serum bilirubin and lactate dehydrogenase (LDH) of the patients when
differentiated by the UGT1A1 (TA) n genotypes (p<0.05). Asymptomatic gallstones were found in 5.9% of patients and
were significantly of the low-activity genotypes sub-group 5 (20%) vs 1(1.3%) p = 0.0033. Although, bilirubin and fetal
hemoglobin (HbF) of patients with gallstones were significantly different from those without gallstone, only the serum
bilirubin was associated with UGT1A1 (TA) n genotypes on multivariate analysis (p < 0.0001).
Conclusion: This study highlights the contribution of UGT1A1 polymorphisms, a non-globin genetic factor, to the
laboratory and clinical manifestations of young Nigerian SCA patients for the first time. It also shows that children with
co-inheritance of low UGT1A1 (TA) n affinity genotypes may be at risk of gallstone, hence the need to follow them up.
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Introduction
Sickle cell disease (SCD) is a common genetic disorder
among Africans. Individuals with the disease have vari-
able clinical expression but homozygosity for the HbS
gene, also known as sickle cell anaemia (SCA), is the
most severe form [1]. Children with SCA have chronic
hemolysis, leading to accumulation of serum bilirubin
and consequent gallstones [2]. Bilirubin is a tetrapyrol
that results from the breakdown of heme in red blood
cells. At moderate levels, it protects against oxidative
stress and inflammatory injuries, and some infectious
diseases [3–5]. However, excessive bilirubin levels, as
seen in chronic hemolysis, have been linked to increased
incidence of gallstones [1, 2, 5]. In children with SCA,
this risk increases with advancing age with a cumulative
incidence of approximately 50% by adulthood and some
of them may need cholecystectomy [2, 6, 7].
Uridine diphosphate glucuronosyltransferase 1A isoform
1 (UGT1A1) is a member of the superfamily of phase II
conjugating enzymes that aids the elimination of bilirubin,
drugs and a vast variety of endogenous and exogenous sub-
strates by adding a glucuronide moiety to the substrates [8,
9]. Genetic mutations resulting in absence or severely re-
duced UGT1A1 activity leads to Criggler-Najjar syndrome
which is characterized by severely elevated serum bilirubin
and increased risk of kernicterus [10]. However, variations
in (TA) n tandem repeat sequence within the TATA box
promoter region affect UGT1A1 gene expression and the
activity of its (TA) n four alleles, namely; (TA) 5, 6, 7, and
8, leading to moderate elevation of serum bilirubin [8, 9].
There is a negative association between the UGT1A1 and
repeat length of the four alleles attributable to the decreas-
ing promoter activity acting via altered affinity for the
TATA–binding protein [8, 9]. The promoter activity leads
to functional changes such that, genotype (TA)5/5 is con-
sidered to have ~ 20% increased expression i.e. high activity
in comparison to genotype (TA) 6/6 known as the wild-
type with normal activity. In addition, genotypes heterozy-
gous and or homozygous for (TA)7 and (TA)8 alleles have
approximately between 30 and 50% reduced expression i.e.
low activity, compared to the wild-type [8]. However, geno-
types (TA)7/7, 7/8 & 8/8 have the lowest activity [2, 8, 9]
and (TA)7/7 has been described generally as genetic hall-
mark for Gilbert syndrome [2, 11]. There is an inverse rela-
tionship between the serum bilirubin levels across these
subgroups and the degree of genotype activity. To this end,
individuals with low-activity genotypes have elevated levels
of serum bilirubin and are, therefore, subjected to the
modulating effects of higher serum bilirubin levels includ-
ing susceptibility to gallstones [2, 8, 9, 11].
Despite the huge burden of SCA in Africa [1], with
Nigeria having the highest burden of SCA in the world
[12], there is little understanding of the contributions of
genetic modifiers of SCA phenotypes in the country. To
the best of our knowledge, there are no data on the ef-
fects of UGT1A1 polymorphisms on the clinical expres-
sion of Nigerian SCA patients. The aims of this study
were to determine the distribution of UGT1A1 (TA) n
genotypes among a group of young SCA patients and
healthy controls and also determine the influence of the
UGT1A1 (TA) n genotypes on the laboratory parameters
and clinical events among the young SCA patients.
Methods
Study participants and settings
The study was conducted on 101 hydroxyurea-naïve chil-
dren and adolescents with SCA (Homozygous SS) aged
between 2 and 21 years (median of 9 years) who are regu-
lar attendees at the paediatric haematology unit of the
Ekiti State University Teaching Hospital (EKSUTH), Ado
Ekiti, Ekiti State, in Southwest Nigeria. They were all in
steady state at the time of recruitment. Steady state was
defined as being free from any acute event(s) for at least 1
month and transfusion free for at least 4 months. Sixty
four genetically independent and unrelated children, who
accompanied their siblings to or attended the paediatrics
outpatients’ well-child clinic of the hospital served as the
controls. Participants with confirmed or suspected liver or
other chronic diseases apart from SCA were excluded.
Also excluded were the few SCA patients on regular blood
transfusion and/or hydroxyurea.
Ethical approval
The study was approved by the Ethics and Research
Committee of EKSUTH no: A67/2016/03/003. Because
the DNA analysis was done at the hematology and
hemotherapy centre, University of Campinas, the study
was also approved by the University of Campinas Ethics
Committee no: CAAE 54031115.9.0000.5404. Written
informed consent of parents/caregivers as well as pa-
tients’ assents and consents were obtained as applicable
after explaining the purpose of the study to them in
clear and plain language.
Data collection
Clinical and laboratory data
Information regarding the steady-state laboratory pa-
rameters and clinical events of the patients were re-
trieved from their hospital records. Average of at least
two steady state results of laboratory parameters per-
formed between 3 to 6 months intervals by standard
techniques were recorded for each participants. The
steady state parameters included the complete blood
performed by Sysmex KX21N Hematology analyser (Sys-
mex Corporation, Kobe, Japan). The serum lactate de-
hydrogenase (LDH), bilirubin, were measured with
standard techniques. The quantitative assessment of
haemoglobin pattern (HbF and HbS), was done by high
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performance liquid chromatography (HPLC, Bio-Rad
Variant D10, USA).
Other information retrieved from patients’ charts in-
cluded the biodata and details of the clinical evolution of
SCA such as number of vaso-occlussive crisis (VOC) i.e.
severe bone pain crises that disrupt daily activities and re-
quired admission and/or administration of opioids within
the preceding 1 year, leg ulcer, priapism, overt osteonecro-
sis and/or overt stroke as well as presence of gallstone as
determined by serial abdominal ultrasound scans con-
ducted on the patients as clinically indicated. In addition,
the clinical records of the patients with gallstones were ex-
amined for the presence or absence of symptoms, and or
treatment(s) for gallstone complications. The definitions
of clinical events were as previously described [13].
Genetic studies
These were carried out at the Centro de Hematologia e
Hemoterapia (Hemocentro), UNICAMP, Campinas, São
Paulo State, Brazil. SCA was initially diagnosed by
haemoglobin electrophoresis and high performance li-
quid chromatography (HPLC) in Nigeria.
The genomic DNA of each participant was extracted
from peripheral blood leukocytes by Qiagen QIAamp
DNA Blood Mini Kit, (Cat No. 51104 Germany), according
to the manufacturer’s protocols and used to confirm the
molecular diagnosis of SCD by polymerase chain reaction
(PCR). The DNA purity and concentration were evaluated
on Nanodrop ND-1000™ Spectrophotometer (NanoDrop
Technologies, Inc., DE, USA). PCR for exon 1 of HBB gene
amplification was performed according to the following
protocol in 30 μL volume: 150 ng of genomic DNA; 1X
Colorless GoTaq® Flexi Reaction Buffer (Promega Corpor-
ation, Madison, USA); 2mM MgCl2; 0.2mM of dNTP
mix; 0.2 μM of each primer (Integrated DNA Technolo-
gies, Coralville, Iowa) named P1: TCCTAAGCCAGTGC
CAGAAG and P5: TCATTCGTCTGTTTCCCATTC [14]
and 1U of GoTaq® Flexi DNA Polymerase (Promega Cor-
poration, Madison, USA). Thermal cycle conditions were
as follow: preheating at 96 °C for 2min, and then 35 cycles
of amplification, with 30 s at 96 °C for denaturation, 30 s at
58 °C for annealing, and 60 s at 72 °C for elongation. The
PCR product (771 bp) was submitted to sequencing reac-
tion by the following conditions: 30 ng PCR product, 1,
0 μL BigDye Terminator v3.1 Ready Reaction Mix
(AppliedBiosystems, Foster City, CA, USA), 1X BigDye Re-
action Buffer, 2 μM of primer (P1 or P5). After thermal
cycling (preheating at 96 °C for 2min, followed by 25 cycles
of 96 °C for 15 s, 58 °C for 5 s, 60 °C for 4min), the sequen-
cing reaction product was precipitated by ammonium acet-
ate and ethanol method, dried at 65 °C and re-suspended
in 10 μL of Hi-Di Formamide for electrophoresis. Ampli-
fied fragments were separated by capillary electrophoresis
on an ABI3500 Genetic Analyzer (Applied Biosystems,
CA).
The UGT1A1 rs8175347 SNP identification was per-
formed by Polymerase Chain Reaction (PCR) as previously
described [15, 16], with some modifications. Briefly, the
PCR reaction was prepared in 30 μL volume with 100 ng of
genomic DNA; 1X Reaction Buffer (BIOTOOLS B&M
Labs, Spain); 2.16mM MgCl2; 1.33mM of dNTP mix; 133
nM of each primer: UGT1A1_*F: 5′-FAM /GTCACGT-
GACACAGTCAAAC − 3′ (*labelled with fluorescein ami-
dite – 6-FAM) and UGT1A1_R: 5′ CAACAGTATCTTCC
CAGCATG − 3′) (Integrated DNA Technologies, Coral-
ville, Iowa), and 1U Taq DNA Polymerase (BIOTOOLS
B&M Labs, Spain). Thermal cycle conditions were as fol-
low: preheating at 96 °C by 2min, followed by 25 cycles of
96 °C for 30 s, 58 °C for 40 s, and 72 °C for 40 s. An ended
step at 72 °C for 30min was performed to promote adeny-
lation of the PCR products. Fragment analysis was per-
formed by Capillary electrophoresis on ABI3500 Genetic
Analyzer and sizes of amplicons were calculated by Gene
Mapper v4.1 Software (both Applied Biosystems, Carlsbad,
CA) - the fragments ranged from 197 to 203 bp, corre-
sponding to (TA)5 - (TA)8 repeats (Additional file 1: Figure
S1). Based on literature data, the UGT1A1 (TA) n geno-
types were further classified into four subgroups namely:
Wild-type (normal), low-, intermediate-, and high-activity
subgroups as previously described [2, 8, 9, 11]. All DNA
studies were carried out blinded regardless of the clinical
and laboratory parameters of the participants.
Data analysis
Statistical analysis was performed with the GraphPad
Prism Program, version 5 for Windows (San Diego, Cali-
fornia, USA). The normal distribution of the quantitative
variables was verified by the Kolmogorov-Smirnov and
Shapiro-Wilk tests. The frequencies of variables were de-
scribed and the significance of differences between
quantitative variables across groups of patients was
assessed using the Kruskal-Wallis analysis of variance
(ANOVA) for ≥3groups, and Mann-Whitney test for
two groups. Chi-square or Fisher’s exact tests were used
as appropriate for the categorical variables. Odd ratios
were obtained by applying logistic regression to deter-
mine the effects of UGT1A1 promoter polymorphism
using the UGT1A1 (TA) n genotype as the independent
variable and other outcomes of interest as the dependent
variables. The test for Hardy-Weinberg equilibrium was
performed using the R-Project for statistical computing
web tool available at https://www.R-project.org. Level of
significance was set at P < 0.05 for all statistical analyses.
Results
The 101 patients with SCA consisted of 66 males and 35
females with median age of 9 and a range 2 - 21 years.
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The controls were made up of 19 sickle cell trait (HbAS)
and 45 haemoglobin HbAA, median age of 8, range 2 -
18 years (p = 0.4260), and 41 males. The SCA patients
have been on follow up for a median of 4 years, range 1–
14 years.
UGT1A1 (TA) n alleles and genotypes
Four (TA) n alleles: (TA)5, 6, 7, and 8 were found with
gene frequencies of 0.11, 0.43, 0.41 and 0.05 respectively.
The alleles were associated with 10 genotypes: TA5/5, 5/
6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8, 8/8 (Table 1). The
wild-type (normal) (TA) 6/6), low (TA) 7/7, 7/8, 8/8),
intermediate (TA) 5/7,5/8, 6/7, 6/8), and high (TA) 5/5,
5/6), enzyme activity genotypes were found in 24.8, 24.8,
41.5%, & 8.9% patients and 20.3, 15.6, 61%, & 3.1% con-
trols respectively. The low activity genotypes were found
in 25 (24.7%) patients and 10 (15.6%) of the controls
(P = 0.1773). Homozygous (TA) n TA7/7 was found in
22 (21.7%) patients and 5 (7.8%) controls p = 0.018
(Table 1). The observed genotype distributions of the
patients and control group were not significantly differ-
ent from the values expected under Hardy-Weinberg
equilibrium (x2 = 15.10, df = 9, p = 0.09), and (x2 = 11.86,
df = 9, p = 0.22), respectively.
Effects of UGT1A1 genotype on serum bilirubin and other
laboratory parameters of patients
Both the total bilirubin and unconjugated bilirubin levels
showed distinct quantitative patterns across the
UGT1A1 (TA) n genotype subgroups with the low-
activity genotype group having the highest levels of
serum bilirubin (p < 0.0001). The LDH also showed a
similar pattern (p = 0.0002). However, this was not dem-
onstrated in the other laboratory parameters (Table 2).
The stratification of the individual UGT1A1 (TA) n ge-
notypes separately shows that (TA)7 and (TA) 8 alleles
were associated with higher levels of both serum biliru-
bin and LDH in general (Additional file 2: Table S1).
Effects of UGT1A1 (TA) n genotype on clinical events
Asymptomatic gallstones were found in 6 (5.9%) pa-
tients. Gallstones were significantly more common in
patients with low-activity genotypes compared to all the
other remaining genotype subgroups 5 (20%) vs 1(1.3%)
p = 0.0033, (Table 3). These were 2 females and 4 males;
the two females were aged 10 and 13 years respectively,
while the males were aged 10, 13, 15 and 16 years re-
spectively. Four of the patients with gallstone had TA 7/
7 genotypes, the remaining two each had TA 7/8, or TA
Table 1 Allele and genotype frequencies of UGT1A1 promoter polymorphisms among participants
Variables SCA (N = 101) AS (N = 19) AA (N = 45)
Freq n (%) Freq n (%) Freq n (%)
Allelotypes
(TA) 5 18 (11.7) 2 (6.7) 10 (12.5)
(TA)6 67 (43.5) 16 (53.3) 28 (35.0)
(TA)7 61 (39.6) 10 (33.3) 37 (46.2)
(TA)8 8 (5.2) 2 (6.7) 5 (6.3)
UGT1A1 Genotypes
TA5/5 0 (0) 0 (0) 1 (2.2)
TA5/6 9 (8.9) 0 (0) 1 (2.2)
TA5/7 6 (6.0) 1 (5.2) 8 (17.7)
TA5/8 3 (2.9) 0 (0) 0 (0)
TA6/6 25 (24.7) 8 (42.1) 5 (11.1)
TA6/7 31 (30.7) 7 (36.8) 21 (46.7)
TA6/8 2 (2.0) 1 (5.2) 1 (2.2)
TA7/7 22 (21.7) 1 (5.2) 4 (8.9)
TA7/8 2 (2.0) 1 (5.2) 4 (8.9)
TA8/8 1 (1.0) 0 (0) 0 (0)
UGT1A1 Genotypes by degree of Activity
Low-Activity genotypes TA (7/7, 7/8, 8/8) 25 (24.8) 2 (10.5) 8 (17.8)
Intermediate-Activity genotypes (TA6/7, TA6/8), TA5/7, TA5/8, 42 (41.5) 9 (47.4) 30 (66.7)
Normal Activity genotypes i.e. (Wild Type) TA6/6 25 (24.8) 8 (42.1) 5 (11.1)
High-Activity genotypes TA5/5, TA5/6, 9 (8.9) 0 (0) 2 (4.4)
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6/7. No significant relationship was found with the other
clinical events.
Comparison of laboratory parameters between patients
with and without gallstones
There were significant differences between the serum
bilirubin and HbF levels in patients with gallstones when
compared with those without. No difference was ob-
served in the LDH and age of the two groups. Further-
more, when those with gallstones were compared with
age- and sex-matched patients within the same UGT1A1
(TA) n genotype subgroup, only serum bilirubin and
HbF showed significant differences between the two
groups (Table 4).
Table 2 Influence of UGT1A1 (TA) n genotype on laboratory parameters of patients






c. Normal activity UGT1A1
genotypes (i.e Wild type)
N = 25




Wallis Test) P values
(a vs b vs c vs d)
Biochemical and
haematologic
Median (Range) Median (Range) Median (Range) Median (Range)
Total Bilirubin (mg/dl) 2.8 (1.2–8.1) 1.8 (0.8–4.6) 1.4 (0.4–3.8) 1.4 (0.5–2.8) < 0.0001**1
Unconjugated Bilirubin (mg/
dl)
1.8 (0.6–6.3) 0.8 (0.1–3.3) 0.6 (0.1–2.3) 0.5 (0.3–1.6) < 0.0001** 1
LDH (IU/L) 987 (296–1860) 798 (215–1489) 789 (340–1417) 287 (197–800) 0.0002** 2
AST (IU/L) 46 (18–89) 37 (8–89) 42 (7–89) 39 (18–89) 0.4837**
ALT (IU/L) 25 (4–65) 19 (7–77) 20 (7–44) 12 (4–34) 0.216**
Hb conc (g/dl) 7.3 (6.3–10) 7.5 (6.3–9.7) 7.2 (6.2–10) 7.9 (7–8.8) 0.608**
MCV (fl) 80.6 (66.9–104.1) 82.3 (60.3–10.2) 77.3 (63.9–96.3) 81 (55.9–115) 0.642**
RBC (× 1012/L) 2.7 (1.9–4.1) 2.7 (1.8–4.1) 2.9 (1.8–4.8) 2.8 (2.2–3.9) 0.258**
WBC (× 109/L) 13 (8.5–26) 13.4 (6.1–29.3) 13.3 (7–25) 12.2 (7.6–23.1) 0.889**
Platelet (× 109/L) 367 (118–771) 349 (159–601) 361 (108–669) 391 (135–832) 0.955**
HbF (%) 9.7 (1.3–20.6) 8.2 (1.7–24.4) 10.7 (2.5–32) 9.4 (0.9–28.5) 0.86**
HbS (%) 80 (71–91.5) 82 (44–91.5) 80 (44–88.3) 80 (65–89) 0.90**
HbA2 (%) 1.6 (0.5–3.5) 1.7 (0.2–3.8) 1.5 (0.2–4.0) 1.1 (0.3–3.1) 0.3147**
Significant p values are indicated in bold fonts
HbF Fetal hemoglobin, RBC Red blood cell, Hb Hemoglobin concentration, HbS Hemoglobin S, HbA2 Hemoglobin A2, MCV Mean corpuscular volume, WBC White
blood cell count, LDH Lactate dehydrogenase, AST Aspartate transaminase, ALT Alanine transaminase
** = Kruskal-Wallis Test with Dunn’s multiple comparison post-hoc tests with differences in *1 = (a vs b), (a vs c), (a vs d) only; *2 = (a vs d), (b vs d), (c vs d) only
Table 3 Influence of UGT1A1 (TA) n genotype on clinical events of patients












P value a vs
(b + c + d)
VOC rate per year 2 (0–6) 1.5 (0–6) 1 (0–6) 0 (0–6) 0.2218*
Overt Stroke 1 2 1 0 1.000†
No overt stroke 24 40 24 9
Osteonecrosis 1 2 2 0 1.000†
No osteonecrosis 24 40 23 9
Leg ulcer 0 2 4 0 0.331†
No Leg ulcer 25 40 21 9
Gallstones 5 1 0 0 0.0033†
No Gallstone 20 41 25 9
Priapism (Male only event, N = 66)
Priapism 2 3 0 0 0.594†
No Priapism 15 25 16 5
Significant p values are indicated in bold fonts
VOC Vaso-occlussive crisis
* = Mann-Whitney Test, † = Fisher’s exact test
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Relationship between UGT1A1 (TA) n genotypes and
other parameters by multivariate analysis
Unconjugated bilirubin was significantly associated with
the low activity UGT1A1 (TA) n genotypes (Adjusted
Odd Ratio (1.08), 95% Confidence interval (1.034768–
1.127873), P < 0.0001). Also, significant association was
found with the total bilirubin when it was used in place
of unconjugated bilirubin in the logistic regression
model (Adjusted Odd Ratio (1.05), 95% Confidence
interval (1.029172–1.089832), P < 0.0001). No association
was found with the other laboratory parameters.
Discussion
There are gaps in the understanding of the impacts of gen-
etic modifiers on SCA phenotype among African patients.
Given the distinct segregation of genetic markers among
different populations, it is pertinent that more studies are
carried out among diverse ethnic cohorts to fully under-
stand the impact of genetic polymorphisms in SCA.
This study confirms the variability of bilirubin levels
based on the activity of the UGT1A1 (TA) n genotypes as
previously reported [2, 4, 5, 8, 9]. However, we are not
aware of any previous study that has described the stratifi-
cation of LDH among SCA patients based on UGT1A1
(TA) n genotype activity as found in this study. While the
UGT1A1 modulation of serum bilirubin levels is well
understood [2, 17, 18], the exact mechanism through
which UGT1A1 could be associated with LDH is not clear.
However, it should be noted that they are both markers of
hemolysis [19]. Given the association of LDH with some
phenotypes of SCA [19, 20], there is need to further
unravel the link between LDH and UGT1A1 activity.
Gilbert syndrome (GBS) has been described in individ-
uals with the TA7/7 genotype [2, 4, 11, 17]. The propor-
tion of patients with TA7/7 genotype in this study (21.7%)
is higher than between 3 and 18% described among Euro-
peans [21, 22] and Brazilians of different descents [23–25].
Similarly, it is higher than the 6% found among Kuwaiti
SCA patients [26] and the 5 to 11% among other Africans
[11, 22]. However, it is lower than the 32% described
among the SCA patients in the USA [27]. Nevertheless,
the TA7/7 genotype prevalence in this study, is compar-
able to between 18.2 and 20.3% earlier described among
Nigerians with non-SCD related illnesses [28, 29]. How-
ever, the higher preponderance of TA7/7 among the pa-
tients compared to the controls in the present study is not
clear but may be due to the low sample size.
Besides the TA7/7 genotype, the other UGT1A1 (TA) n
genotypes found in this study have been described among
Africans [9, 22]. These observations indicate that the
UGT1A1 (TA) n genotype is quite variable among Niger-
ians. It also confirms the suggestions that the expression
of the UGT1A1 (TA) n genotype variants is heterogeneous
among Africans compared to Caucasians [9, 21, 22].
Our finding that the low-activity UGT1A1 (TA) n
genotype was associated with gallstones confirms previ-
ous observations that SCA patients with the low-activity
UGT1A1 (TA) n genotypes especially the TA7/7, are at
Table 4 Comparison of parameters in patients with and without gallstones
Parameter Patients with gallstones (N = 6)
Median (Range)
Patients without gallstones (N = 95)
Median (Range)
P value
Total Bilirubin (mg/dl) 6.4 (2.8–8.1) 1.8 (0.4–6.7) 0.0001*
Unconjugated Bilirubin (mg/dl) 4.7 (0.9–6.3) 0.79 (0.1–5) 0.0007*
LDH (IU/L) 1004 (592–1860) 794 (197–1750) 0.1263*
HbF (%) 4.7 (1.3–6.8) 10.2 (0.9–32) 0.0107*
Hb (g/dl) 7.1 (6.3–8.8) 7.5 (6.2–10) 0.4210*
Age in years 11.5 (8–16) 9 (2–21) 0.1368*
Sex
Male (n = 66) 4 62 1.000†
Female (n = 35) 2 33
Parameter Patients with gallstones (N = 6)
Median (Range)
Matched peers without gallstones within
same UGT1A1 genotype activity group N = 10
Median (Range)
P value
Total Bilirubin (mg/dl) 6.4 (2.8–8.1) 2.2 (1.9–3.2) 0.0023*
Unconjugated Bilirubin (mg/dl) 4.7 (0.9–6.3) 1.2 (1.0–2.0) 0.0020*
LDH (IU/L) 1004 (592–1860) 890 (340–1603) 0.628*
HbF (%) 4.7 (1.3–6.8) 14.7 (4.2–17.9) 0.022*
Hb (g/dl) 7.1 (6.3–8.8) 8.0 (6.5–8.9) 0.137*
NB Significant P values are indicated in bold fonts
HbF Fetal hemoglobin, Hb Hemoglobin concentration, LDH Lactate dehydrogenase
* = Mann-Whitney test, † = Fisher’s Exact test
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risk of developing gallstones [2, 6, 7, 11, 17]. In addition
to the TA7/7 genotype, other authors [11, 30], have re-
ported that some other low-activity UGT1A1 (TA) n ge-
notypes like TA7/8 and TA8/8 predispose SCA patients
to gallstones as found in this study.
The proportion of patients with asymptomatic gallstones
in this study (5.9%), is comparable to between 4 and 6%
earlier reported among Nigerian children of similar age to
our SCA cohorts [31–33]. This is also similar to the 4%
found in Ghana [34], a close neighbour to Nigeria. How-
ever, it is lower than between 9 and 58% reported for some
other African [35–37], Italian [38], American [39], and Bra-
zilian [40] patients. These observations possibly highlight
the variations in propensity to gallstone development
among children with SCA from different backgrounds.
Despite the observation that the UGT1A1 (TA) n low
-activity genotype is a leading factor in hyperbilirubinemia
and lithogenesis among SCA patients [2, 6, 7, 41, 42], the
impact of UGT1A1 polymorphism on the phenotypic ex-
pression of the Nigerian SCA patients was unknown prior
to this study as none of the previous studies from Nigeria
examined the UGT1A1 of the patients [31–33]. There is
therefore, the need to closely follow up these patients
given that, results of follow-up studies have indicated
higher prevalence of gallstones and its complications with
increasing age of SCA patients [2, 26, 30, 37, 40].
Beyond bilirubin metabolism and gallstone develop-
ment, it has been speculated that individuals with the low-
activity genotypes may be subjected to some other modu-
lating effects of higher serum bilirubin levels that are often
associated with these genotypes [2, 8, 9, 11]. These other
modulating effects include protection against oxidative
stress, inflammatory injuries, and reduced susceptibility to
infections [2–5, 8, 9, 43]. We did not observe any associ-
ation between the UGT1A1 (TA) n genotypes and any of
the other SCA downstream events/phenotypes examined
(VOC, leg ulcer, priapism, overt stroke and osteonecrosis)
that could be perturbed by both inflammatory and oxida-
tive injuries in SCA. However, the small sample size of the
study makes it difficult to draw any firm conclusion.
The major limitations of the present study are its
hospital-based nature and the small sample. Despite these,
it was able to confirm that UGT1A1 (TA) n genotypes are
tightly associated with bilirubin and LDH levels, and the
development of gallstones among young Nigerians with
SCA. In addition, it also suggests that the pathway to ele-
vated serum bilirubin and gallstone development, among
our study cohort, may not be exclusively driven by
hemolysis but also by UGT1A1 polymorphisms.
Conclusions
This study shows that children with co-inheritance of
low UGT1A1 (TA) n affinity genotypes may be at risk of
gallstone, thus highlighting the need to closely follow
them up for early identification of possible gallstone
complications and provision of appropriate interven-
tion(s). In addition, it highlights the contribution of
UGT1A1 polymorphisms, a non-globin genetic factor, to
the laboratory and clinical manifestations of young Ni-
gerian SCA patients for the first time.
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